Boehringer Inks $265 Million Alzheimer’s R&D Deal For Ablynx’s Nanobodies Technology
This article was originally published in The Pink Sheet Daily
Executive Summary
The contract includes options for drug development in other neurocognitive diseases, the company tells “The Pink Sheet” DAILY.
You may also be interested in...
Boehringer's Restless Leg Syndrome Drug To Be Promoted By Neurology/Primary Care Reps
Parkinson's agent Mirapex gains supplemental indication, will compete with GSK's Requip.
Wyeth Boosting TNF Inhibitor R&D Via Ablynx Deal
Discovery and development deal for Ablynx’ preclinical Nanobodies could build on Wyeth’s experience with Enbrel.
Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.